FDA Approves Novo Nordisk's Prandin
Prandin (repaglinide) is an oral diabetes medicine that helps control blood sugar levels.
This medication lowers blood sugar by causing the pancreas to produce insulin.
Prandin is used together with diet and exercise to treat type 2 (non-insulin dependent) diabetes. Other diabetes medicines are sometimes used in combination with repaglinide if needed
Prandin is used to reduce blood sugar levels in people with type 2 diabetes (the kind that does not require insulin shots). It's prescribed when diet and exercise alone fail to correct the problem. A combination of Prandin and a second diabetes drug can be prescribed if either drug alone proves insufficient.
Prandin (repaglinide) has been approved for the treatment of Type 2 diabetes. It is the first approved product in a new chemical class (meglitinide class) of orally administered drugs for the treatment of Type 2 diabetes, and was developed to manage meal related (prandial) glucose loads.
Prandin is often prescribed to lower blood sugar levels in people with type 2 diabetes. It works by helping the pancreas produce more insulin. The drug comes in tablet form and is taken by mouth before each meal. If you skip a meal, you should also skip your dose of this medication. Side effects are possible; common ones include low blood sugar, upper respiratory tract infections, and headaches.